EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia

Ryan Williamson, Marta Zurawska iD, Adrian Valadez iD, Emma Harlan iD, Marc H Scheetz iD, Michael N Neely iD, Paul R Yarnold iD, Mengjia Kang iD, Helen K Donnelly iD, Franciso Martinez iD, Erin Korth iD, Rachel L Medernach iD und 7 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01766-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Ryan Williamson und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Tazobactam, Piperacillin, Piperacillin, Tazobactam Drug Combination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Midwestern University's Office of Research and Sponsored Programs, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimizing antibiotic exposures in hospital-acquired pneumonia (HAP) is crucial; however, dosing decisions often overlook target levels for the beta-lactamase inhibitor tazobactam (TAZ), and the impact of renal dysfunction and renal replacement therapy on TAZ pharmacokinetics (PK) remains poorly described. We developed a population PK model of TAZ using 162 plasma samples from 35 ICU patients with HAP, including those receiving continuous renal replacement therapy (CRRT). TAZ concentrations were quantified using validated LC-MS/MS methods. A one-compartment model was fit using Monolix, with clearance modeled as a function of creatinine clearance, CRRT effluent flow rate, and intermittent hemodialysis. Monte Carlo simulations assessed the probability of unbound TAZ concentrations exceeding 1, 2, or 4 mg/L for 100% of the interval between 24 and 48 h across intermittent, extended, and continuous infusion (CI) regimens, stratified by renal function and CRRT. TAZ clearance was driven by renal function and CRRT flow rate. All regimens achieved ≥90% probability of target attainment (PTA) at thresholds of 1–2 mg/L. At 4 mg/L, PTA fell below 90% in patients with creatinine clearance ≥150 mL/min for all regimens, with low-dose CI performing the worst. High-dose CI improved PTA at this higher threshold but may increase the risk of piperacillin overexposure. TAZ exposures sufficient for enzymatic beta-lactamase inhibition are generally achieved with standard dosing for lower thresholds but not for more aggressive targets (e.g., high extended-spectrum β-lactamase expression), particularly in patients with preserved or augmented renal function, who may require therapeutic drug monitoring or alternative therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsTazobactamPiperacillinPiperacillin, Tazobactam Drug CombinationHealthcare-Associated Pneumoniabeta-Lactamase InhibitorsHumansMaleFemaleIntensive Care UnitsMiddle AgedAgedMonte Carlo MethodContinuous Renal Replacement TherapyMicrobial Sensitivity Tests

Stichwörter der Autor:innen

population pharmacokineticsrenal dysfunctiontarget attainmenttazobactam

Substanzen

Anti-Bacterial AgentsTazobactamPiperacillinPiperacillin, Tazobactam Drug Combinationbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.
  • Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois, USA.
  • Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
  • Departments of Pharmacology and Biomedical Sciences, College of Graduate Studies, Midwestern University, Downers Grove, Illinois, USA.
  • Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute, Children's Hospital of Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Marta Zurawska, Adrian Valadez, Emma Harlan, Marc H Scheetz, Michael N Neely, Paul R Yarnold, Mengjia Kang, Helen K Donnelly, Franciso Martinez, Erin Korth, Rachel L Medernach, Sophia H Nozick, Alan R Hauser, Egon A Ozer, Estefani Diaz, Alexander V Misharin, Richard G Wunderink, Nathaniel J Rhodes

Förderung

  • NIH HHS
  • Midwestern University's Office of Research and Sponsored Programs
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NLM NIH HHS
  • NIA NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Williamson, R., Zurawska, M., Valadez, A., Harlan, E., Scheetz, M. H., Neely, M. N., Yarnold, P. R., Kang, M., Donnelly, H. K., Martinez, F., Korth, E., Medernach, R. L., Nozick, S. H., Hauser, A. R., Ozer, E. A., Diaz, E., Misharin, A. V., Wunderink, R. G., & Rhodes, N. J. (2026). Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01766-25

Vancouver

Williamson R, Zurawska M, Valadez A, Harlan E, Scheetz MH, Neely MN, et al. Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01766-25

BibTeX
@article{Williamson2026,
  author = {Williamson, Ryan and Zurawska, Marta and Valadez, Adrian and Harlan, Emma and Scheetz, Marc H and Neely, Michael N and Yarnold, Paul R and Kang, Mengjia and Donnelly, Helen K and Martinez, Franciso and Korth, Erin and Medernach, Rachel L and Nozick, Sophia H and Hauser, Alan R and Ozer, Egon A and Diaz, Estefani and Misharin, Alexander V and Wunderink, Richard G and Rhodes, Nathaniel J},
  title = {Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01766-25}
}
Kostenlos starten →